PTEN and cancer: Thus, new stratifications based on up- and downregulation of PTEN DUBs can ensure PTEN protein localization and activity and optimize PTEN DUB-targeted therapies, which may be specifically tailored to human cancers that do not exhibit homozygous (biallelic) loss of PTEN.